Article

Benralizumab: The Immuno-Pharmacological State of the Art

2024-06-14

Abstract excerpt

Eosinophils are key therapeutic targets in severe asthma as they accumulate in tissues, resulting in local damage through the release of toxic mediators. Benralizumab is a monoclonal antibody with a direct anti-eosinophilic activity that has proved significant clinical efficacy in patients with severe eosinophilic asthma, and its use in real-life went well beyond what we had expected from the pivotal trials, espec...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 803914bd-c82c-55d1-b952-f7eb4ae22577
DOI: 10.20944/preprints202406.1014.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Benralizumab: The Immuno-Pharmacological State of the ArtDOI 10.20944/preprints202406.1014.v1Read

Benralizumab for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype.Semantic proximity Read

Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma.Semantic proximity Read

Biologics in severe asthma: the overlap endotype - opportunities and challenges.Semantic proximity Read

An early Indian experience with benralizumab - A compendium on severe asthma cases: a case seriesSemantic proximity Read

Inflammation in Asthma: Mechanistic Insights and the Role of Biologics in Therapeutic FrontiersSemantic proximity Read

Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient.Semantic proximity Read

Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies.Semantic proximity Read

Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma.Semantic proximity Read

Targeted therapeutics for severe refractory asthma: monoclonal antibodies.Semantic proximity Read

Treatment of Chronic Spontaneous Urticaria With Benralizumab: Report of Primary Endpoint Completer Analysis, Secondary and Exploratory EndpointsSemantic proximity Read

Clinical Potential of Eosinophil-Derived Neurotoxin in Asthma Management.Semantic proximity Read

Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab.Semantic proximity Read